Danaher (DHR) — Q3 2026 Earnings Preview
Key Factors to Watch for Q3 2026
| Factor | What to Watch / Why It Matters |
|---|---|
| Core Revenue Growth | Guidance is for +2% to +3% YoY; underlying growth ex-respiratory expected at ~5%. Acceleration vs. Q2 is key. |
| Segment Performance | Life Sciences: guided to +3% to +4% YoY; Biotechnology: mid-single digit; Diagnostics: flat. |
| Bioprocessing Trends | Focus on shipment timing, order growth, and whether Q2’s customer-driven pushouts reverse in Q3/Q4. |
| Respiratory Testing Impact | Respiratory testing is a ~250 bps YoY headwind in Q3; normalization expected in Q4. |
| EPS and Margin Progression | Raised FY26 adjusted EPS guidance to $8.45–$8.60; Q3 margin guide at ~26.5%. |
| Masimo Integration | Early close in June; look for initial accretion, revenue synergies, and margin impact. |
| StatLab Acquisition | Pending close by year-end; watch for commentary on integration and contribution expectations. |
| Capital Deployment | $900M buyback in Q2; further M&A or buyback signals given strong balance sheet. |
| End-Market Recovery | Management expects continued recovery, especially in Life Sciences and Diagnostics; watch for evidence of this. |
Summary and Conclusions
- Q3 2026 Preview: Danaher is guiding to core revenue growth of +2% to +3% YoY, with underlying growth (excluding respiratory testing) expected at ~5%. Life Sciences is expected to be the main driver, with Biotechnology and Diagnostics contributing more modestly.
- Key Watchpoints: Investors should focus on the pace of end-market recovery, especially in Life Sciences, and whether bioprocessing shipment delays seen in Q2 reverse in Q3/Q4. Respiratory testing remains a headwind but is expected to normalize by Q4.
- EPS and Margins: The company raised full-year adjusted EPS guidance to $8.45–$8.60, reflecting strong Q2 performance and the earlier-than-expected close of the Masimo acquisition. Q3 adjusted operating margin is guided to ~26.5%.
- M&A and Capital Allocation: Masimo is expected to be immediately accretive; StatLab is pending. Danaher continues to have significant balance sheet flexibility for further capital deployment.
- Comparables: Q3 2025 saw core revenue growth of +3.0% YoY, so the upcoming quarter is not facing an unusually tough comparable, but the bar is set for sequential acceleration in underlying growth.
Recent Results — Quarterly Financial Snapshot
Actuals: Quarterly Results ($M except per-share data)
| Quarter | Revenue | Core Revenue Growth | Adj. Diluted EPS | Adj. Op. Margin | Free Cash Flow | Notes |
|---|---|---|---|---|---|---|
| Q2 2026 | 6,265 | +3.0% | $1.94 | 27.1% | 1,265 | Core ex-respiratory: +4.5% |
| Q1 2026 | 5,951 | +0.5% | $2.06 | 30.2% | 1,085 | Core ex-respiratory: +3.0% |
| Q4 2025 | 6,838 | +2.5% | $2.23 | 28.3% | 1,769 | Core ex-respiratory: +4.0% |
| Q3 2025 | 6,053 | +3.0% | $1.89 | 27.9% | 1,370 |
*Source: Company filings and press releases. Adj. EPS and margin are non-GAAP.
Segment Core Revenue Growth — Recent Quarters
| Quarter | Biotechnology | Life Sciences | Diagnostics | Total Company |
|---|---|---|---|---|
| Q2 2026 | +2.5% | +5.5% | +2.0% | +3.0% |
| Q1 2026 | +7.0% | +0.5% | -4.0% | +0.5% |
| Q4 2025 | +6.0% | +0.5% | +2.0% | +2.5% |
| Q3 2025 | +6.5% | -1.0% | +3.5% | +3.0% |
Guidance — Q3 and Full Year 2026
Q3 2026 Guidance
| Metric | Guidance | Context/Notes |
|---|---|---|
| Core Revenue Growth | +2% to +3% YoY | Respiratory testing headwind ~250 bps |
| Core Revenue ex-Respiratory | ~+5% YoY | Acceleration vs. Q2 |
| Adj. Operating Margin | ~26.5% |
Full Year 2026 Guidance (as of Q2 2026)
| Metric | Guidance | Context/Notes |
|---|---|---|
| Core Revenue Growth | +3% to +4% YoY | Raised from prior +3% to +6% range |
| Core Revenue ex-Respiratory | +mid-single digit | |
| Adj. Diluted EPS | $8.45–$8.60 | Raised from $8.35–$8.55 |
| Respiratory Testing Revenue | ~$1.6B | Lowered from $1.6–$1.7B |
What Happened Last Year? (Q3 2025)
- Q3 2025 Actuals: Revenue $6,053M, core revenue growth +3.0% YoY, adjusted diluted EPS $1.89, adjusted operating margin 27.9%.
- Segment Trends: Biotechnology +6.5%, Life Sciences -1.0%, Diagnostics +3.5%.
- Context: Q3 2025 was a solid quarter with beats on top and bottom line, driven by strength in bioprocessing and better-than-expected respiratory revenue at Cepheid. Life Sciences was soft, particularly in academic/government, but pharma showed modest recovery.
- Comparables: Q3 2026 is not facing an unusually tough comparable; Q3 2025 was a "beat" quarter but not a high-water mark.
Intra-Quarter Commentary and Management Tone
- Q2 2026 Call: Management highlighted strong Life Sciences performance, robust bioprocessing orders (mid-teens growth), and continued end-market recovery. Bioprocessing revenue was impacted by shipment timing at a few large customers, but underlying demand and order trends remain strong.
- Bioprocessing: Management expects shipment delays (~$100M+) to shift into 2027, but does not see broad-based demand weakness. Equipment revenue returned to growth in Q2 after several quarters of sequential order growth.
- Life Sciences: Outperformed expectations in Q2, with improved funding environment in biotech and stabilization in academic/government. Abcam delivered its best quarter since acquisition.
- Diagnostics: Ex-respiratory, core growth was +5% in Q2. China policy headwinds are moderating, and new product launches (e.g., DxI 9000, p-Tau217 assay) are supporting growth.
- Masimo: Closed earlier than expected; delivered high single-digit revenue growth in H1 2026 and is expected to be immediately accretive.
- StatLab: Pending acquisition, expected to close by year-end, will strengthen Leica Biosystems’ workflow offering.
Consensus Estimates — Next Two Quarters
| Quarter | Revenue ($M) | Gross Margin (%) | EBITDA ($M) | Net Income ($M) | EPS (GAAP) |
|---|---|---|---|---|---|
| Q3 2026 | 6,554 | 58.2 | 1,929 | 1,354 | 1.30 |
| Q4 2026 | 7,575 | 59.3 | 2,528 | 1,835 | 1.97 |
*Consensus figures are not actuals.
Most Important Factors for Q3 2026
- Core Revenue Growth Trajectory: Is Danaher on track to exit 2026 at mid-single-digit growth, as guided? Underlying growth ex-respiratory is the key metric.
- Bioprocessing Revenue and Orders: Will shipment delays seen in Q2 reverse, and does order momentum continue? Any signs of broader demand softness would be negative.
- Life Sciences Momentum: Can the segment sustain or accelerate the improved growth seen in Q2, especially as academic/government stabilizes and biotech funding converts to orders?
- Diagnostics Execution: Is mid-single-digit growth ex-respiratory sustainable? Are China headwinds continuing to moderate?
- Masimo Integration: Early signs of accretion, revenue/margin synergy realization, and impact on Diagnostics segment.
- Capital Allocation: Any new M&A, buybacks, or updates on StatLab closing.
- Margin and EPS Progression: Is the company on track for the raised EPS and margin targets?
Conclusion
Danaher enters Q3 2026 with positive momentum, especially in Life Sciences and Diagnostics, and robust order trends in bioprocessing despite some shipment timing issues. The company is not facing a particularly tough YoY comparable, but investors will expect to see sequential acceleration in underlying growth, continued order strength, and early benefits from the Masimo acquisition. Management’s ability to deliver on the raised EPS and margin guidance, while navigating respiratory testing headwinds and capitalizing on end-market recovery, will be the key focus areas for the upcoming report.
